Highest-materiality recent filing
Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal
Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.
Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals
Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.
Madrigal gains full control over Rezdiffra patent term extensions from Roche
Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.
Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1
Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.
Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit
Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.
Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones
Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.
$350M initial term loan funded at close; $150M delayed draw available through Dec 2027.
Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy
Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.
Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis
Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.
Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.
Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%
Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.
Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B
Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.
Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up
Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.
Madrigal raises ~$86M from underwriters' option exercise; total offering ~$660M
Underwriters exercised option to purchase 346,153 shares at $260.00 per share.
Madrigal raises ~$574M in public offering for Rezdiffra launch
Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.
Madrigal receives FDA accelerated approval for Rezdiffra, first NASH therapy
FDA grants accelerated approval for Rezdiffra in NASH with F2-F3 fibrosis; first approved therapy for NASH.
Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.
On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.
On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.
Max materiality 1.00 · Median 0.75 · Most common event earnings